BrainTale Has Presented at the European Academy of Neurology and the World Parkinson Congress the Interest of Its Digital Biomarker Platform for the Early and Differential Diagnosis of Parkinson’s Disease

BrainTale, a medtech deciphering white matter to enable better brain care, spin-off of the Paris Region Greater Hospitals, presented preliminary results during the European Academy of Neurology (Budapest, July 1 – 4, 2023) and the World Parkinson congress (Barcelona, July 4 – 7, 2023) demonstrating the interest of its digital biomarker platform for the early and differential diagnosis of Parkinson’s disease. Vincent Perlbarg, co-founder, scientific director and president of BrainTale, has presented the results supporting the interest of BrainTale’s digital biomarker platform for the care of patients suffering from the disease and the development of new therapies.Long underestimated in neuroscience, white matter, which represents 60% to 80% of the human brain, plays a key role in its proper functioning, development, and aging, whether normal or pathological. Accordingly, since its creation in 2018, BrainTale has been developing non-invasive, accessible, effective and clinically validated measurement and prediction tools for patients suffering from brain diseases.Affecting around 8.5 million people worldwide, the incidence of Parkinson’s disease continues to rise and is still diagnosed far too late to effectively slow its progression, despite white matter lesions being identifiable at an early stage, particularly in the basal ganglia responsible for initiating and harmonizing muscle movements. Results are presented July 1-4 in the EAN and Thursday, July 6 at 11am:30h CET with poster titled “Evaluation of a clinically validated digital platform for the delivery of diffuse MRI biomarkers in parkinsonism”.Prospective data were obtained from 81 subjects (46 subjects with Parkinson’s disease [PD], 18 subjects with tau pathology [PSP], 10 subjects with ⍺-synuclein [(MSAc]) and 7 subjects with -synuclein [(MSAc]) multisystem atrophy with [MSAp] phenotypes) was studied with the team of Professor Stéphane Lehéricy, head of the Department of Neuroradiology at the Pitié-Salpêtrière Hospital, Major Hospitals of Île-de-France, France).The results demonstrated the ability to discriminate patient populations based on quantitative white matter assessments that were statistically different (p<0.05) for different types of subjects. The main results are: decreased anisotropy ratio (AF) between MSAc and PSP groups compared with PD group and increased radial diffusivity (RD) between MSAc group compared with PD group.These preliminary data highlight the relevance and sensitivity of BrainTale’s white matter biomarkers for Parkinsonian syndromes, including early stages of Parkinson’s disease. It paves the way for the possibility of using these brain biomarkers not only for early, non-invasive and reliable differential diagnosis of Parkinson’s syndromes, but also to help accelerate the development of therapies. new. With a new version of the brainTale care biomarker platform available from February 2023, centers and partners equipped with BrainTale technology can now improve the care of these patients and help with diagnosis patient safety.
“These initial results obtained in patients with Parkinson’s syndromes monitored prospectively confirm the value of these biomarkers for differentiating tremor etiologies. In the long term, this could lead to improved management of such patients, particularly when symptoms are equivocal,”
Prof. Stéphane Lehéricy, Head of the Neuroradiology Department, Paris Region Greater Hospitals, France.
“The presentation of those first results in collaboration with Prof. Lehéricy’s teams at these two major conferences strengthens BrainTale’s strong commitment to patients suffering from Parkinson and Parkinson’s related symptoms, for whom diagnostic and therapeutic options remain highly imperfect. The entire BrainTale team is highly committed to providing our solutions to all stakeholders,”
Vincent Perlbarg, co-founder, president and Chief Scientific Officer of the company.
Next Post

Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK

Sensorion, a pioneering clinical-stage biotech company dedicated to the development of new therapies to restore, treat, and prevent hearing loss disorders, today announced that it has submitted an Application Initial clinical trial (CTA) for OTOF-GT for the UK Medicines and Health Agency. The Healthcare Products Regulatory Authority (MHRA). The Phase […]